HPC — Hydration Pharmaceuticals Co Income Statement
0.000.00%
Last trade - 00:00- AU$2.74m
- -AU$2.29m
- $3.20m
Annual income statement for Hydration Pharmaceuticals Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.76 | 6.13 | 9.1 | 4.3 | 3.2 |
| Cost of Revenue | |||||
| Gross Profit | 1.34 | 2.79 | 4.7 | 1.9 | 1.62 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4.5 | 14.4 | 19.7 | 11.5 | 8.88 |
| Operating Profit | -0.744 | -8.29 | -10.6 | -7.23 | -5.67 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.744 | -8.95 | -10.6 | -7.23 | -5.67 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.744 | -8.95 | -10.6 | -7.23 | -5.67 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -0.744 | -8.95 | -10.6 | -8.1 | 2.67 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.744 | -8.95 | -10.6 | -8.1 | 2.67 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.021 | -0.06 | -0.063 | -0.036 | -0.021 |
| Dividends per Share |